Effects of polycystin‑1 N‑terminal fragment fusion protein on the proliferation and apoptosis of rat mesangial cells.

Mesangial proliferative glomerulonephritis (MsPGN) is characterized by widespread mesangial cell proliferation and an accumulation of extracellular matrix (ECM) in the mesangial area. In a previous study we developed a polycystin‑1 N‑terminal fragment (PC‑1 NF) fusion protein that inhibits the proliferation of cyst‑lining epithelial cells in autosomal dominant polycystic kidney disease. In addition, the PC‑1 NF fusion protein arrests the cell cycle of cancer cells at the G0/G1 phase, inhibiting their proliferation. In the present study, the effect of the PC‑1 NF fusion protein on MsPGN was investigated. It was found that the PC‑1 NF fusion protein inhibited the proliferation of rat mesangial cells and induced G0/G1 phase arrest and apoptosis in vitro. PC‑1 NF fusion protein treatment also resulted in a decrease in mRNA expression levels of proliferating cell nuclear antigen, cyclin D1 and B‑cell lymphoma‑2 (Bcl‑2) and an increase in mRNA expression levels of Bcl‑2‑associated X protein (Bax) and p21Waf1. Furthermore, a decrease in Bcl‑2, c‑fos, c‑jun and protein kinase C‑α protein levels was observed, whereas Bax protein levels increased. Additionally, PC‑1 NF fusion protein induced ECM degradation and inhibited ECM expansion. The results also demonstrated that PC‑1 NF fusion protein treatment resulted in a decrease in type IV collagen and tissue inhibitor of metalloproteinase mRNA levels but an increase in matrix metalloproteinase 2 mRNA levels. In combination, these results suggest that the PC‑1 NF fusion protein inhibits proliferation, promotes apoptosis and induces ECM degradation in MsPGN rats. This study offers novel perspectives for the treatment of MsPGN.

[1]  Soo Oh,et al.  Polycystic kidney disease , 2020, Springer New York.

[2]  Chun Luo,et al.  Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells , 2012, Journal of Neuro-Oncology.

[3]  H. Kleinman,et al.  The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells. , 2011, International journal of oncology.

[4]  P. Ditonno,et al.  Androgen deprivation therapy affects BCL-2 expression in human prostate cancer. , 2011, International journal of oncology.

[5]  J. Tanus-Santos,et al.  A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury. , 2011, The Science of the total environment.

[6]  Z. Dong,et al.  The Function of Heterodimeric AP-1 Comprised of c-Jun and c-Fos in Activin Mediated Spemann Organizer Gene Expression , 2011, PloS one.

[7]  F. Fervenza,et al.  Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. , 2011, Seminars in nephrology.

[8]  H. Marti,et al.  Single Application of Low-Dose Mycophenolate Mofetil-OX7-Immunoliposomes Ameliorates Experimental Mesangial Proliferative Glomerulonephritis , 2011, Journal of Pharmacology and Experimental Therapeutics.

[9]  Ting He,et al.  p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell , 2010, BMC Cancer.

[10]  M. Caplan,et al.  The cell biology of polycystic kidney disease , 2010, The Journal of cell biology.

[11]  Hyung Gyun Kim,et al.  Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. , 2010, Biochemical pharmacology.

[12]  Hongyu Luo,et al.  Ran Overexpression Leads to Diminished T Cell Responses and Selectively Modulates Nuclear Levels of c-Jun and c-Fos* , 2009, The Journal of Biological Chemistry.

[13]  R. Mancinelli,et al.  H3 Histamine Receptor–Mediated Activation of Protein Kinase Cα Inhibits the Growth of Cholangiocarcinoma In vitro and In vivo , 2009, Molecular Cancer Research.

[14]  P. Courtoy,et al.  Metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 ectodomain decreases endocytic clearance of endometrial matrix metalloproteinase-2 and -9 at menstruation. , 2009, Endocrinology.

[15]  Rong Zheng,et al.  Polycystin‐1 induced apoptosis and cell cycle arrest in G0/G1 phase in cancer cells , 2008, Cell biology international.

[16]  P. Jungers,et al.  Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  M. Ergin,et al.  Expression of Fas, Bcl‐2 and p53 molecules in glomerulonephritis and their correlations with clinical and laboratory findings * , 2005, Nephrology.

[18]  C. Mei,et al.  [Preparation and characterization of monoclonal antibody against N-terminal domain of polycystin 1]. , 2004, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.

[19]  Ivan Stamenkovic,et al.  Extracellular matrix remodelling: the role of matrix metalloproteinases , 2003, The Journal of pathology.

[20]  Alessandra Boletta,et al.  PKD1 Induces p21waf1 and Regulation of the Cell Cycle via Direct Activation of the JAK-STAT Signaling Pathway in a Process Requiring PKD2 , 2002, Cell.

[21]  G. Germino,et al.  Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. , 2000, Molecular cell.

[22]  H. Takahashi,et al.  Effects of Tissue Fixation and Processing on Proliferating Cell Nuclear Antigen (PCNA) Immunohistochemistry , 1992, Acta pathologica japonica.

[23]  D. Lovett,et al.  Proteinases and glomerular matrix turnover. , 1992, Kidney international.

[24]  Tian-mei Sun.  Evaluation of polycystin-1 N-terminal peptide on the proliferation and apoptosis of cystic-lining epithelial cells in human ADPKD , 2005 .